Compliance to oseltamivir and subsequent occurrence of self-reported adverse drug reactions among nursery and primary school children following exposure to influenza a(h1n1)v

Scottish Medical Journal

Volumn 56, Issue 2, 2011, Pages 1-3

  van Velzen, E ^a,b   Hutchinson, S ^c   Penrice, G ^d   Ahmed, S ^d   McMenamin, J ^a  

^a EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Adverse drug reaction; Child; H1N1 subtype; Influenza a virus; Patient compliance

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; CHILD; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; EXPOSURE; FATIGUE; FEMALE; HEALTH SURVEY; HUMAN; INFECTION PREVENTION; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; NAUSEA; PARENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRESCRIPTION; SCHOOL CHILD; SELF REPORT; TREATMENT DURATION; VOMITING; EPIDEMIC; INFANT; INFLUENZA; INFLUENZA VIRUS A H1N1; QUESTIONNAIRE; SCHOOL; STATISTICS; UNITED KINGDOM;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HEALTH SURVEYS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MEDICATION ADHERENCE; OSELTAMIVIR; QUESTIONNAIRES; SCHOOLS; SCOTLAND;

EID: 79959334466     PISSN: 00369330     EISSN: None     Source Type: Journal    
DOI: 10.1258/smj.2010.010017     Document Type: Article

References (9)

1. Heymann AD, Hoch I, Valinsky L, Kokia E, Steinberg DM. School closure may be effective in reducing transmission of respiratory viruses in the community. Epidemiol Infect 2009;137:1369-76
2. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 2007:pCD002744
3. Scottish Government, Scottish Index of Multiple Deprivation (SIMD). See http://www.scotland.gov.uk/Topics/Statistics/SIMD/ (last checked 24 January 2011)
4. Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care 2007;19:134-40
5. Summary of Product Characteristics Oseltamivir phosphate, in UK Medicines and Healthcare Regulatory Agency (MHRA). See http://www.mhra.gov.uk/Safetyinformation/Swinefluinformation/Antiviralmedicines/CON046589 (last checked 25 August 2009)
6. HPA, Health Protection Agency. Summary of Prescribing Guidance for the Treatment and Prophylaxis of Influenza-like Illness: Treatment Phase. 2009, London
7. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomized controlled trials. BMJ 2009;339:b3172
8. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill 2009;14:19287
9. Wallensten A, Oliver I, Lewis D, Harrison S. Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England. Euro Surveill 2009;14:19285